Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
Share:
(Reuters) - The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.The biosimilar, Ontruzant, is sold by Merck Sharp & Dohme Corp, a unit of Merck & Co Inc , and is developed by Samsung Bioepis Co Ltd, which is a joint venture between Samsung BioLogics and Biogen Inc .The approval https://twitter.com/FDA_Drug_Info/status/1086327386059157504 comes just a few weeks after the health regulator gave..